17,500 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by Strs Ohio

Strs Ohio purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 17,500 shares of the biopharmaceutical company’s stock, valued at approximately $298,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Schonfeld Strategic Advisors LLC grew its holdings in shares of TG Therapeutics by 164.5% during the third quarter. Schonfeld Strategic Advisors LLC now owns 1,367,400 shares of the biopharmaceutical company’s stock valued at $11,431,000 after buying an additional 850,507 shares during the last quarter. 683 Capital Management LLC acquired a new position in TG Therapeutics during the 3rd quarter valued at about $11,286,000. Charles Schwab Investment Management Inc. increased its holdings in TG Therapeutics by 2.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,112,682 shares of the biopharmaceutical company’s stock worth $9,302,000 after purchasing an additional 31,872 shares in the last quarter. Rafferty Asset Management LLC raised its stake in shares of TG Therapeutics by 183.2% in the third quarter. Rafferty Asset Management LLC now owns 856,837 shares of the biopharmaceutical company’s stock worth $7,163,000 after purchasing an additional 554,309 shares during the last quarter. Finally, Jump Financial LLC lifted its holdings in shares of TG Therapeutics by 342.2% in the third quarter. Jump Financial LLC now owns 472,972 shares of the biopharmaceutical company’s stock valued at $3,954,000 after purchasing an additional 366,012 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on TGTX. B. Riley upped their price target on TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, February 5th. StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. LADENBURG THALM/SH SH reissued a “buy” rating and set a $39.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a report on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.00.

Insider Activity

In related news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the sale, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.20% of the company’s stock.

TG Therapeutics Stock Down 1.1 %

TGTX opened at $13.32 on Tuesday. TG Therapeutics, Inc. has a twelve month low of $6.46 and a twelve month high of $35.67. The company’s 50-day moving average price is $15.06 and its two-hundred day moving average price is $14.27. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of 666.00 and a beta of 2.30. The company has a quick ratio of 5.18, a current ratio of 5.92 and a debt-to-equity ratio of 0.62.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. The company had revenue of $43.97 million for the quarter, compared to analysts’ expectations of $40.06 million. During the same quarter in the previous year, the firm posted ($0.39) EPS. As a group, equities analysts expect that TG Therapeutics, Inc. will post -0.11 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.